# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k111919   
B. Purpose for Submission: Addition of 12 new recombinant allergens to a cleared device   
C. Measurand: Twelve new recombinant allergen-specific IgE analytes: Two Hazel nut: (rCor a 8 and rC 10), six Timothy (rPhl p1, rPhl p2, rPhl p6, rPhl p7, rPhl p12, rPhl and p5b) and four Birc PR-10, rBet v 2 Profilin, rBet v4 and rBet v 6)   
D. Type of Test: Fluoroenzymeimmunoassay, Quantitative and Semi-quantitative   
E. Applicant: Phadia AB   
F. Proprietary and Established Names: ImmunoCAP Allergen f425, Allergen component rCor a 8, Hazel nut ImmunoCAP Allergen f428, Allergen component rCor a 1, PR-10, Hazel nut ImmunoCAP Allergen $\mathrm { g } 2 0 5$ , Allergen component rPhl p1, Timothy ImmunoCAP Allergen $\mathbf { g } 2 0 6$ , Allergen component rPhl p2, Timothy ImmunoCAP Allergen g209, Allergen component rPhl p6, Timothy ImmunoCAP Allergen g210, Allergen component rPhl p7, Timothy ImmnuoCAP Allergen g212, Allergen component rPhl p12, Timothy ImmunoCAP Allergen g215, Allergen component rPhl p5b, Timothy ImmunoCAP Allergen t215, Allergen component rBet v 1, PR-10, Birch ImmunoCAP Allergen t216, Allergen component rBet v 2 Profilin, Birch ImmunoCAP Allergen t220, Allergen component rBet v4, Birch ImmunoCAP Allergen t225, Allergen component rBet v 6, Birch

# G. Regulatory Information:

1. Regulation section: 21 CFR $\$ 866.5750$ , Radioallergosorbent (RAST) immunological test system   
2. Classification: Class II   
3. Product code: DHB - System, Test, Radioallergosorbent (RAST), Immunological   
4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of allergen specific IgE in human serum or plasma. ImmunoCAP Specific IgE is to be used with instruments Phadia 100, Phadia 250, and Phadia 1000. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings, and is to be used in clinical laboratories.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for use statement(s): For prescription use only   
4. Special instrument requirements: ImmunoCAP Specific IgE is to be used with the instruments Phadia 100, Phadia 250 and Phadia

1000

# I. Device Description:

The ImmunoCAP system is a fully integrated and automated system for the determination of specific IgE in human blood serum or sodium heparin plasma sample. It is comprised of general, test and method specific reagents for Phadia 100, Phadia 250 and Phadia 1000 test system modules, as well as instrument and data management software.

The general ImmunoCAP reagents include ImmunoCAP Specific IgE Conjugate, ImmunoCAP Specific IgE Curve Control, ImmunoCAP Specific IgE Calibrators, Specific IgE anti-IgE ImmunoCAP, Allergen ImmunoCAP carriers, ImmunoCAP development solution and stop solution. The method specific reagents consist of individual purified allergen (native or recombinant) covalently coupled to a support in a plastic housing.

# J. Substantial Equivalence Information:

1. Predicate device name(s) and 510(k) numbers: UniCAP Specific IgE Assay/ Conjugate 100/ Conjugate 400 (k051218) and UniCAP Specific IgE Assay (k962274) Comparison with predicate:

3.

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>ImmunoCAP Specific IgE is an in vitromeasurement of allergen specific IgE inhuman serum or plasma. It is intendedfor in vitro diagnostic use as an aid inthe clinical diagnosis of IgE mediatedallergic disorders in conjunction withother clinical findings</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Number of calibrators</td><td rowspan=1 colspan=1>Six</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample matrix</td><td rowspan=1 colspan=1>Serum and plasma (sodium heparin)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>β-Galactosidase-anti-IgE (mousemonoclonal antibody) for allImmunoCAP</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Basic principle</td><td rowspan=1 colspan=1>Fluoroenzymeimmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>40 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Process time</td><td rowspan=1 colspan=1>2 hours 30 minutes for Phadia 100.1 hour 45 minutes for Phadia 250 and1000.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Incubation temperature</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3">Differences</td></tr><tr><td>Item</td><td>Device</td><td>Predicate</td></tr><tr><td>Allergens</td><td>Individual recombinant proteins: Two Hazel nut: rCor a 8 and rCor a 1 PR-10; six Timothy: rPhl p1, rPhl p2, rPhl p6, rPhl p7, rPhl p12, rPhl p5b; and four Birch: rBet v 1 PR-10, rBet</td><td>Whole allergens comprising multiple proteins from purified native allergen source</td></tr><tr><td>Assay type</td><td>v 2 Profilin, rBet v4, rBet v6 Quantitative</td><td>Semi-Quantitative</td></tr><tr><td colspan="1" rowspan="1">Laboratory settings</td><td colspan="1" rowspan="1">Clinical laboratories</td><td colspan="1" rowspan="1">Clinicallaboratories andphysician officelaboratories.</td></tr><tr><td colspan="1" rowspan="1">Instruments</td><td colspan="1" rowspan="1">Phadia 100, Phadia 250 andPhadia 1000</td><td colspan="1" rowspan="1">UniCAP 100</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI I/LA20-A2: Analytical Performance Characteristics of Immunological Assays for Human Immunoglobulin E (IgE) Antibodies, March 2009   
CLSI EP5-A: Evaluation of Precision Performance of Quantitative Measurement Methods, August 2004   
CEN 13640: 2002 Stability Testing of in vitro Diagnostic Reagents.   
CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation.   
Radioallergosorbent Test (RAST) Methods for Allergen-Specific Immunoglobulin E (IgE) 510(k)s; Final Guidance for Industry and FDA

L. Test Principle:

The allergen of interest covalently coupled to the ImmunoCAP solid phase, reacts with the specific IgE in the patients plasma/serum sample. After washing away non specific IgE, enzyme-labeled antibodies against IgE are added to form a complex. After incubation, unbound enzyme-anti-IgE is washed away and the bound complex is then incubated with the developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The higher the response value, the more specific IgE present in the specimen. To evaluate the rest results, the response for the patient samples are transformed to concentrations with the use of a calibration curve.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

# Within-Lot imprecision:

Imprecision of the individual allergen components was evaluated by using two plasma samples $0 . 3 5 \pm 2 5 \%$ and ${ \geq } 0 . 7 \mathrm { k U _ { A } } / \mathrm { l }$ ) tested four times per day, for 20 operating days (a total of 80 replicates per allergen). The study data shown below were performed on a Phadia 250 instrument according to the ImmunoCAP Specific IgE Directions for Use. Similar assay precision was demonstrated on the Phadia 100 and Phadia 1000 instruments.

Allergen Group: Hazel nut   

<table><tr><td rowspan=1 colspan=1>Allergen</td><td rowspan=1 colspan=1>ComponentNumber</td><td rowspan=1 colspan=1>Mean(kUA/l)</td><td rowspan=1 colspan=1>BetweenDays CV%</td><td rowspan=1 colspan=1>Within runCV%</td><td rowspan=1 colspan=1>TotalCV%</td></tr><tr><td rowspan=2 colspan=1>f425</td><td rowspan=2 colspan=1>rCor a 8</td><td rowspan=1 colspan=1>2.37</td><td rowspan=1 colspan=1>2.64</td><td rowspan=1 colspan=1>3.36</td><td rowspan=1 colspan=1>4.28</td></tr><tr><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>3.08</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>3.60</td></tr><tr><td rowspan=2 colspan=1>f428</td><td rowspan=2 colspan=1>rCor a 1,PR-10</td><td rowspan=1 colspan=1>2.23</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>2.12</td><td rowspan=1 colspan=1>3.36</td></tr><tr><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>3.41</td><td rowspan=1 colspan=1>2.06</td><td rowspan=1 colspan=1>3.99</td></tr></table>

Allergen Group: Timothy   

<table><tr><td colspan="1" rowspan="1">Allergen</td><td colspan="1" rowspan="1">ComponentNumber</td><td colspan="1" rowspan="1">Mean(kUA/l)</td><td colspan="1" rowspan="1">BetweenDays CV%</td><td colspan="1" rowspan="1">Within runCV%</td><td colspan="1" rowspan="1">TotalCV%</td></tr><tr><td colspan="1" rowspan="2">g205</td><td colspan="1" rowspan="2">rPhl p1</td><td colspan="1" rowspan="1">2.09</td><td colspan="1" rowspan="1">4.01</td><td colspan="1" rowspan="1">2.15</td><td colspan="1" rowspan="1">4.55</td></tr><tr><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">4.77</td><td colspan="1" rowspan="1">2.39</td><td colspan="1" rowspan="1">5.34</td></tr><tr><td colspan="1" rowspan="2">g206</td><td colspan="1" rowspan="2">rPhl p2</td><td colspan="1" rowspan="1">2.71</td><td colspan="1" rowspan="1">2.67</td><td colspan="1" rowspan="1">3.21</td><td colspan="1" rowspan="1">4.18</td></tr><tr><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">3.55</td><td colspan="1" rowspan="1">3.40</td><td colspan="1" rowspan="1">4.91</td></tr><tr><td colspan="1" rowspan="2">g209</td><td colspan="1" rowspan="2">rPhl p6</td><td colspan="1" rowspan="1">1.71</td><td colspan="1" rowspan="1">2.69</td><td colspan="1" rowspan="1">3.65</td><td colspan="1" rowspan="1">4.54</td></tr><tr><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">4.58</td><td colspan="1" rowspan="1">3.74</td><td colspan="1" rowspan="1">5.92</td></tr><tr><td colspan="1" rowspan="2">g210</td><td colspan="1" rowspan="2">rPhl p7</td><td colspan="1" rowspan="1">5.07</td><td colspan="1" rowspan="1">2.19</td><td colspan="1" rowspan="1">1.95</td><td colspan="1" rowspan="1">2.93</td></tr><tr><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">3.40</td><td colspan="1" rowspan="1">1.92</td><td colspan="1" rowspan="1">3.91</td></tr><tr><td colspan="1" rowspan="2">g212</td><td colspan="1" rowspan="2">rPhl p12</td><td colspan="1" rowspan="1">2.26</td><td colspan="1" rowspan="1">3.31</td><td colspan="1" rowspan="1">2.73</td><td colspan="1" rowspan="1">4.29</td></tr><tr><td colspan="1" rowspan="1">0.42</td><td colspan="1" rowspan="1">3.80</td><td colspan="1" rowspan="1">3.05</td><td colspan="1" rowspan="1">4.88</td></tr><tr><td colspan="1" rowspan="2">g215</td><td colspan="1" rowspan="2">rPhl p5b</td><td colspan="1" rowspan="1">2.83</td><td colspan="1" rowspan="1">2.36</td><td colspan="1" rowspan="1">2.45</td><td colspan="1" rowspan="1">3.40</td></tr><tr><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">4.50</td><td colspan="1" rowspan="1">2.19</td><td colspan="1" rowspan="1">5.00</td></tr></table>

Allergen Group: Birch   

<table><tr><td rowspan=1 colspan=1>Allergen</td><td rowspan=1 colspan=1>ComponentNumber</td><td rowspan=1 colspan=1>Mean(kUA/l)</td><td rowspan=1 colspan=1>BetweenDays CV%</td><td rowspan=1 colspan=1>Within runCV%</td><td rowspan=1 colspan=1>TotalCV%</td></tr><tr><td rowspan=2 colspan=1>t215</td><td rowspan=2 colspan=1>rBet v 1PR-10</td><td rowspan=1 colspan=1>3.29</td><td rowspan=1 colspan=1>3.15</td><td rowspan=1 colspan=1>2.85</td><td rowspan=1 colspan=1>4.25</td></tr><tr><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>3.57</td><td rowspan=1 colspan=1>2.69</td><td rowspan=1 colspan=1>4.47</td></tr><tr><td rowspan=2 colspan=1>t216</td><td rowspan=2 colspan=1>rBet v 2Profilin</td><td rowspan=1 colspan=1>2.63</td><td rowspan=1 colspan=1>3.29</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>4.19</td></tr><tr><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>3.07</td><td rowspan=1 colspan=1>2.81</td><td rowspan=1 colspan=1>4.16</td></tr><tr><td rowspan=2 colspan=1>t220</td><td rowspan=2 colspan=1>rBet v4</td><td rowspan=1 colspan=1>1.79</td><td rowspan=1 colspan=1>4.07</td><td rowspan=1 colspan=1>2.31</td><td rowspan=1 colspan=1>4.68</td></tr><tr><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>5.76</td><td rowspan=1 colspan=1>3.93</td><td rowspan=1 colspan=1>6.98</td></tr><tr><td rowspan=2 colspan=1>t225</td><td rowspan=2 colspan=1>rBet v6</td><td rowspan=1 colspan=1>1.73</td><td rowspan=1 colspan=1>3.15</td><td rowspan=1 colspan=1>2.29</td><td rowspan=1 colspan=1>3.89</td></tr><tr><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>3.15</td><td rowspan=1 colspan=1>5.98</td><td rowspan=1 colspan=1>6.76</td></tr></table>

# Lot-to-lot imprecision:

Three lots of each individual allergen were tested using two positive samples $( 0 . 3 5 \pm 2 5 \%$ and ${ \geq } 0 . 7 \mathrm { k U _ { A } } / \mathrm { l }$ ) and one negative sample $( < 0 . 1 \mathrm { k U _ { A } / l } )$ . For each lot the samples were tested in 12 replicates in one assay run. Each lot represented a different preparation of the allergen from routine production.

Allergen Group: Hazel nut   

<table><tr><td rowspan=3 colspan=1>Allergen(Componentnumber)</td><td rowspan=3 colspan=1>Lot</td><td rowspan=1 colspan=5>Sample</td></tr><tr><td rowspan=1 colspan=2>Positive 1</td><td rowspan=1 colspan=2>Positive 2</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Mean(kUA/l)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>Mean(kUA/l)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>Mean(kUA/)</td></tr><tr><td rowspan=3 colspan=1>rCor a 8 (f425)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.83</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.14</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=3 colspan=1>rCor a 1, PR-10(f428)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.08</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.24</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>&lt;0.1</td></tr></table>

Allergen Group: Timothy   

<table><tr><td colspan="1" rowspan="3">Allergen(Componentnumber)</td><td colspan="1" rowspan="3">Lot</td><td colspan="5" rowspan="1">Sample</td></tr><tr><td colspan="2" rowspan="1">Positive 1</td><td colspan="2" rowspan="1">Positive 2</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Mean(kUA/1)</td><td colspan="1" rowspan="1">CV (%)</td><td colspan="1" rowspan="1">Mean(kUA/)</td><td colspan="1" rowspan="1">CV (%)</td><td colspan="1" rowspan="1">Mean(kUA/1)</td></tr><tr><td colspan="1" rowspan="1">Mean(kUA/l)</td><td colspan="1" rowspan="1">CV (%)</td><td colspan="1" rowspan="1">Mean(kUA/l)</td><td colspan="1" rowspan="1">CV (%)</td><td colspan="1" rowspan="1">Mean(kUA/l)</td></tr><tr><td colspan="1" rowspan="3">rPhl p1 (g205)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2.16</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1.81</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">1.91</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="3">rPhl p2 (g206)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2.47</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2.60</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2.52</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="3">rPhl p6 (g209)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1.71</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">0.27</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1.84</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">0.32</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">1.70</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">0.27</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="3">rPhl p7 (g210)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2.88</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2.80</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2.78</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="3">rPhl p12, Profilin(g212)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1.66</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1.93</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">0.32</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2.24</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">0.39</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="3">rPhl p5b (g215)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2.57</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">0.38</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2.60</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">&lt;0.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2.61</td><td colspan="1" rowspan="1">3.6</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">&lt;0.1</td></tr></table>

Allergen Group: Birch   

<table><tr><td rowspan=3 colspan=1>Allergen(Componentnumber)</td><td rowspan=3 colspan=1>Lot</td><td rowspan=1 colspan=5>Sample</td></tr><tr><td rowspan=1 colspan=2>Positive 1</td><td rowspan=1 colspan=2>Positive 2</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Mean(kUA/l)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>Mean(kUA/l)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>Mean(kUA/l)</td></tr><tr><td rowspan=3 colspan=1>rBet v 1, PR-10(t215)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.50</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3.31</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=3 colspan=1>rBet v2, Profilin(t216)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.36</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.51</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.42</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=3 colspan=1>rBet v 4 (t220)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.86</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.73</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.71</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=3 colspan=1>rBet v 6 (t225)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.81</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.86</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.83</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>&lt;0.1</td></tr></table>

# $b$ . Linearity/assay reportable range:

The linearity of the 12 individual allergens was assessed by diluting three positive plasma samples per allergen in negative plasma to provide at least five 2-fold consecutive dilutions. Undiluted and diluted samples were tested in four replicates in one assay run. The assay was performed according to the ImmunoCAP Specific IgE Directions for Use using instrument Phadia 250. For each product, one lot of ImmunoCAP Allergen Component was used. The

ImmunoCAP Specific Total IgE working range is LoD to100 kUA/l.

For each allergen, results of the replicates from all three samples were pooled and analyzed for linearity. Regression statistics for each allergen comparing the observed results to expected results are presented below:

<table><tr><td rowspan=1 colspan=1>ImmunoCAPAllergenComponent</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>r2$</td><td rowspan=1 colspan=1>95% CISlope</td><td rowspan=1 colspan=1>95% CIIntercept</td></tr><tr><td rowspan=1 colspan=1>f425, rCor a 8</td><td rowspan=1 colspan=1>y= 0.99x + 0.01</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.96-1.02</td><td rowspan=1 colspan=1>-0.01 - 0.03</td></tr><tr><td rowspan=1 colspan=1>f428,, rCor a 1</td><td rowspan=1 colspan=1>y=1.01x + (-0.03)</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.01-1.02</td><td rowspan=1 colspan=1>-0.04-(-0.02)</td></tr><tr><td rowspan=1 colspan=1>g205, rPhl p 1</td><td rowspan=1 colspan=1>y = 1.00x + 0.02</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.99- 1.00</td><td rowspan=1 colspan=1>0.01-0.02</td></tr><tr><td rowspan=1 colspan=1>g206, rPhl p 2</td><td rowspan=1 colspan=1>y = 0.99x + 0.04</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.98- 0.99</td><td rowspan=1 colspan=1>0.03- 0.04</td></tr><tr><td rowspan=1 colspan=1>g209, rPhl p 6</td><td rowspan=1 colspan=1>y=1.02x+(-0.01)</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.01- 1.03</td><td rowspan=1 colspan=1>-0.02-0.00</td></tr><tr><td rowspan=1 colspan=1>g210, rPhl p 7</td><td rowspan=1 colspan=1>y = 1.00x+0.02</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.99- 1.02</td><td rowspan=1 colspan=1>0.00- 0.03</td></tr><tr><td rowspan=1 colspan=1>g212, rPhl p 12</td><td rowspan=1 colspan=1>y=0.95x +0.08</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.94-0.96</td><td rowspan=1 colspan=1>0.07- 0.09</td></tr><tr><td rowspan=1 colspan=1>g215, rPhl p 5b</td><td rowspan=1 colspan=1>y=1.01x +(-0.03)</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.01- 1.02</td><td rowspan=1 colspan=1>-0.04-(-0.02)</td></tr><tr><td rowspan=1 colspan=1>t215, rBet v 1</td><td rowspan=1 colspan=1>y = 0.99x + 0.02</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.99- 1.00</td><td rowspan=1 colspan=1>0.02- 0.03</td></tr><tr><td rowspan=1 colspan=1>t216,, rBet v 2</td><td rowspan=1 colspan=1>y=0.94x + 0.07</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.94-0.95</td><td rowspan=1 colspan=1>0.077-0.08</td></tr><tr><td rowspan=1 colspan=1>t220,, rBet v 4</td><td rowspan=1 colspan=1>y = 0.99x + 0.04</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.97-1.00</td><td rowspan=1 colspan=1>0.03-0.05</td></tr><tr><td rowspan=1 colspan=1>t225, rBet v 6</td><td rowspan=1 colspan=1>y= 1.01x</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.00-1.01</td><td rowspan=1 colspan=1>-0.01 - 0.00</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The IgE calibrators are traceable (via an unbroken chain of calibrations) to the $2 ^ { \mathrm { n d } }$ International Reference Preparation (IRP) 75/502 of Human Serum Immunoglobulin E from World Health Organization (WHO).

Stability

Real-time stability - study results were available for Hazel Nut (f425, f428); Timothy $( \mathrm { g } 2 0 5 ,$ , g206, g209, g210, g212, g215) and Birch allergens (t215, t216, t220, t225) and support an unopened shelf-life of 24 months from the date of manufacture when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ . For the real-time study, three lots of each component allergen were stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ . At different time intervals (0, 3, 6, 13 months), a positive and a negative human plasma sample were tested in three replicates in one assay. The results were compared to the results of the same samples tested at time $= 0$ . The study is on-going.

Accelerated stability - studies performed on allergen components Hazel Nut (f425, f428); Timothy (g205, $\mathbf { g } 2 0 6$ , g209, g210, g212, g215) and Birch allergens (t215, t216, t220, t225) support an unopened shelf-life of 24 months from the date of manufacture when stored at 2- $8 \mathrm { { } ^ { \circ } C }$ . For the accelerated study, three lots of component allergens were stored at $3 0 \mathrm { { } ^ { \circ } C }$ for eight weeks. The same lot stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ was used as reference. At four weeks and at eight weeks two positive and one negative control samples (stored human plasma) were tested in duplicate for each storage condition/lot combination. The results support the manufacture’s claim of 24 months. Real-time stability studies are underway for these components and currently support a claim of 13 months.

The stability of the calibration curve, real time, and on-board stability of ImmunoCAP Specific IgE calibrator are detailed in k100999.

d. Detection limit:

The Limit of Blank (LoB) and the Limit of Detection (LoD) were determined for each allergen component on the Phadia 250 in alignment with CLSI EP17-A. The LoB was based on single determinations of 100 negative samples (blank samples) and was estimated as the $9 5 \%$ percentile of the distribution. LoD was calculated according to the equation: $\mathrm { L o D = L o B }$ ${ } + c _ { \beta } { \bf { \times S D } }$ where SD, the standard deviation, was based on 20 determinations of 3 low positive samples, in total 60 determinations.

<table><tr><td rowspan=1 colspan=1>AllergenGroup</td><td rowspan=1 colspan=1>Allergencomponent</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td></tr><tr><td rowspan=2 colspan=1>Hazel Nut</td><td rowspan=1 colspan=1>f425</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.039</td></tr><tr><td rowspan=1 colspan=1>f428</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>0.043</td></tr><tr><td rowspan=6 colspan=1>Timothy</td><td rowspan=1 colspan=1>g205</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.025</td></tr><tr><td rowspan=1 colspan=1>g206</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.015</td></tr><tr><td rowspan=1 colspan=1>g209</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.019</td></tr><tr><td rowspan=1 colspan=1>g210</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.010</td></tr><tr><td rowspan=1 colspan=1>g212</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>0.026</td></tr><tr><td rowspan=1 colspan=1>g215</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>0.026</td></tr><tr><td rowspan=4 colspan=1>Birch</td><td rowspan=1 colspan=1>t215</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>0.022</td></tr><tr><td rowspan=1 colspan=1>t216</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>0.024</td></tr><tr><td rowspan=1 colspan=1>t220</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>0.021</td></tr><tr><td rowspan=1 colspan=1>t225</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.013</td></tr></table>

# e. Analytical specificity:

Specificity of each allergen was verified through competitive inhibition studies in accordance with CLSI I/LA20-A2. Inhibition studies should show an overall dose dependent decrease of free specific IgE antibodies available to bind to the ImmunoCAP Allergen. This dose dependent decrease indicates the presence of antibodies that recognize the allergen; no, or little, decrease in response indicates that there are no antibodies specific to the allergen. The specific inhibition demonstrates the presence of immunologically relevant and reactive allergen bound to the solid phase.

The allergen solution was serially diluted with buffer to show an overall dose dependent inhibition. The unrelated allergen solutions are not further diluted.

Equal volumes of a positive sample and varying dilutions of allergen solution (inhibitor) were premixed. The mixture was incubated in a sample tube at room temperature for 1 hour before being analyzed with the corresponding ImmunoCAP Allergen Component on ImmunoCAP instrument according to the manufacturer’s instructions. The testing was performed in duplicates in one assay run. Mean values were calculated.

The inhibition test was evaluated with inhibition values in $\%$ , calculated according to the formula below:

$$
\left( 1 - \left( { \frac { r - b } { t - b } } \right) \right) \times 1 0 0 = i \%
$$

$\mathbf { r } =$ response [RU]   
${ \mathfrak { b } } =$ background response ( $100 \%$ inhibition) [RU]   
$\mathbf { t } =$ total response ( $0 \%$ inhibition) [RU]   
$\mathrm { i } =$ inhibition

Any negative inhibition $\%$ -values are shown as $0 \%$ inhibition.

Inhibition studies should show an overall dose dependent decrease of free specific IgE antibodies available to bind to the ImmunoCAP Allergen Component resulting in a decrease in measured response, resulting in at least a $50 \%$ decrease of the measured response. At a much higher concentration (about 10 fold), the unrelated inhibitors should not show any appreciable inhibition.

The results of the inhibition with the allergen solution and the unrelated inhibitors indicate that the 12 new allergens contain the immunologically relevant allergen as shown below:

# Allergen Group: Hazel nut

# rCor a 8 (f425), Hazel nut

The rCor a 8 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor (rCor a 8 allergen) at final inhibitor concentration $\mathord { \sim } 5 \mathrm { \mu } \mathrm { g } / \mathrm { m L }$ . The three unrelated inhibitor did not show any significant inhibition at $5 0 0 ~ \mu \mathrm { g / m L }$ .

# rCor a 1, PR-10 (f428), Hazel nut

The rCor a 1, PR-10 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor (rCor a 1, PR-10) at final inhibitor concentration $\sim 5 0 ~ \mathrm { { n g / m L } }$ . The three unrelated inhibitor did not show any significant inhibition at $5 0 0 ~ \mu \mathrm { g / m L }$ .

# Allergen Group: Timothy

# rPhl p 1 (g205), Timothy

The rPhl p 1 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor $( \mathrm { r P h l p } 1 )$ at final inhibitor concentration $\sim 5 0 ~ \mathrm { { n g / m L } }$ . The three unrelated inhibitor did not show any significant inhibition at $1 4 0 ~ \mu \mathrm { g / m L }$ .

# rPhl p 2 (g206), Timothy

The rPhl p 2 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor $\left( \mathrm { r P h l p } 2 \right)$ at final inhibitor concentration $\sim 5 0 ~ \mathrm { { n g / m L } }$ . The three unrelated inhibitor did not show any significant inhibition at $5 0 0 ~ \mu \mathrm { g / m L }$ .

# rPhl p 6 (g209), Timothy

The rPhl p 6 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor $( \mathrm { r P h l p } 6 $ allergen) at final inhibitor concentration ${ \sim } 5 ~ \mu \mathrm { g / m L }$ . The three unrelated inhibitor did not show any significant inhibition at $1 4 0 ~ \mu \mathrm { g / m L }$ .

# rPhl p 7 (g210), Timothy

The rPhl p 7 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor $\mathrm { ( r P h l p 7 }$ allergen) at final inhibitor concentration $\sim 5 0 ~ \mathrm { { n g / m L } }$ . The three unrelated inhibitor did not show any significant inhibition at $5 0 0 ~ \mu \mathrm { g / m L }$ .

# rPhl p 12, Profilin (g212), Timothy

The rPhl p 12, Profilin allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor (rPhl p 12, Profilin allergen) at final inhibitor concentration ${ \sim } 5 ~ \mu \mathrm { g / m L }$ . The three unrelated inhibitor did not show any significant inhibition at $5 0 0 ~ \mu \mathrm { g / m L }$ .

# rPhl p 5b (g215), Timothy

The rPhl p 5b allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor $( \mathrm { r P h l } \ p 5 \mathrm { b } .$ allergen) at final inhibitor concentration $\sim 5 0 ~ \mathrm { { n g / m L } }$ . The three unrelated inhibitor did not show any significant inhibition at $1 4 0 ~ \mu \mathrm { g / m L }$ .

# Allergen Group: Birch

# rBet v 1, PR-10 (t215), Birch

The rBet v 1, PR-10 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor (rBet v 1, PR-10 allergen) at final inhibitor concentration $\sim 5 0 ~ \mathrm { { n g / m L } }$ . The three unrelated inhibitor did not show any significant inhibition at $5 0 0 ~ \mu \mathrm { g / m L }$ .

# rBet v 2, Profilin (t216), Birch

The rBet v 2, Profilin allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor (rBet v 2, Profilin allergen) at final inhibitor concentration $\mathord { \sim } 5 \mathrm { \mu } \mathrm { g } / \mathrm { m L }$ . The three unrelated inhibitor did not show any significant inhibition at $1 4 0 ~ \mu \mathrm { g / m L }$ .

# rBet v 4 (t220) , Birch

The rBet v 4 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor (rBet v 4 allergen) at final inhibitor concentration $\sim 5 0 ~ \mathrm { { n g / m L } }$ . The three unrelated inhibitor did not show any significant inhibition at $2 2 0 ~ \mu \mathrm { g / m L }$ .

# rBet v 6 (t225), Birch

The rBet v 6 allergen Inhibition study showed that $50 \%$ inhibition was achieved with related inhibitor (rBet v 6 allergen) at final inhibitor concentration $\sim 5 0 ~ \mathrm { { n g / m L } }$ . The three unrelated inhibitor did not show any significant inhibition at $2 2 0 ~ \mu \mathrm { g / m L }$ .

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: Refer to clinical studies.

$b$ . Matrix comparison:

Serum, sodium heparin plasma, and EDTA plasma samples were collected from four patients with clinical history of known specific allergies and four nonatopic patients. These samples were tested with the ImmunoCap allergen components .This resulted in a range of results (negative and positive) within each sample. All positive heparin plasma and EDTA plasma samples $( \ge 0 . 3 5 \mathrm { k U _ { A } / L } )$ ) demonstrated acceptable %recovery with the relevant allergens. This study suggests that the three sample matrices are interchangeable.

3. Clinical studies:

a. Clinical sensitivity and Specificity:

The performance of all 12 individual allergen components was compared to a clinical diagnosis of allergy. Atopic samples were obtained from individuals with a clinical history of allergy-like symptoms upon exposure to an allergen as diagnosed by a physician and/or clinical symptoms and/or positive skin prick test to a specific allergen. Information about clinical symptoms and manifestations was available for all atopic samples. 100 negative samples $( < 0 . 3 5 \mathrm { k U _ { A } / L } )$ ) from healthy non-atopic donors were also tested.

# Hazel nut:

ImmunoCAP Allergen f425, rCor a 8

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rCor a 8(f425)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>55</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>155</td></tr></table>

Sensitivity $= 1 0 0 \%$ $( 9 5 \% \mathrm { C I } ; 9 3 . 5 - 1 0 0 \% )$ Specificity $= 1 0 0 \%$

ImmunoCAP Allergen f428, rCor a 1, PR-10   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rCor a 1,PR-10(f428)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>170</td></tr></table>

Sensitivity $= 1 0 0 \%$ ( $9 5 \%$ CI: 94.9 – 100%) Specificity $= 1 0 0 \%$

Timothy: ImmunoCAP Allergen g205, rPhl p 1   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rPhl p 1(g205)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>85</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>185</td></tr></table>

Sensitivity $= 1 0 0 \%$ ( $9 5 \%$ CI: 95.8 – 100%) Specificity $= 1 0 0 \%$

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rPhl p 2(g206)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>147</td></tr></table>

Sensitivity $= 1 0 0 \%$ $9 5 \% \mathrm { C I } { : 9 2 . 5 - 1 0 0 \% } )$ Specificity $= 1 0 0 \%$

ImmunoCAP Allergen g209, rPhl p 6   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rPhl p 6(g209)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>61</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>161</td></tr></table>

Sensitivity $= 1 0 0 \%$ ( $9 5 \%$ CI: 94.1 – 100%) Specificity $= 1 0 0 \%$

ImmunoCAP Allergen g210, rPhl p 7   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rPhl p 7(g210)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>109</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>130</td></tr></table>

Sensitivity $= 7 0 \%$ ( $9 5 \%$ CI: 50.6 – 85.3%) Specificity $= 1 0 0 \%$

ImmunoCAP Allergen g212, rPhl p 12, Profilin   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rPhl p 12,Profilin(g212)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>134</td></tr></table>

Sensitivity $= 1 0 0 \%$ ( $9 5 \%$ CI: 89.7 – 100%) Specificity $= 1 0 0 \%$

ImmunoCAP Allergen g215, rPhl p 5b   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rPhl p 5b(g215)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>167</td></tr></table>

Sensitivity $= 1 0 0 \%$ ( $9 5 \%$ CI: 94.6 – 100%) Specificity $= 1 0 0 \%$

Birch: ImmunoCAP Allergen t215, rBet v 1, PR-10

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rBet v 1,PR-10(t215)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>94</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>194</td></tr></table>

Sensitivity $= 1 0 0 \%$ ( $9 5 \% \mathrm { C I } { : 9 6 . 2 - 1 0 0 . 0 \% } )$ Specificity $= 1 0 0 \%$

ImmunoCAP Allergen t216, rBet v 2, Profilin   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rBet v 2,Profilin(t216)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>139</td></tr></table>

Sensitivity $= 1 0 0 \%$ ( $9 5 \%$ CI: 06.2 – 100%) Specificity $= 1 0 0 \%$

ImmunoCAP Allergen t220, rBet v 4   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rBet v 4(t220)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>102</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>130</td></tr></table>

Sensitivity $= 9 3 \%$ ( $9 5 \%$ CI: 77.9 – 99.2%) Specificity $= 1 0 0 \%$

ImmunoCAP Allergen t225, rBet v 6   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>rBet v 6(t225)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>106</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>130</td></tr></table>

Sensitivity $= 8 0 \%$ ( $9 5 \%$ CI: 61.4 – 92.3%) Specificity $= 1 0 0 \%$

Studies described above were performed on the Phadia 1000 instrument system. The applicant provided studies to show that the Phadia 100 and Phadia 250 instrument system performed similarly to the Phadia 1000.

$b$ . Other clinical supportive data (when a. is not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

The expected value is negative $( < 0 . 3 5 \mathrm { k U _ { A } / L } )$ for a specific allergen in a non-allergic person. The manufacturer recommends a cut-off of $0 . 3 5 \mathrm { k U _ { A } / L }$ . Each laboratory should establish its own expected range of values.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.